Literature DB >> 23801832

Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India.

Reena Kumari1, Vineet Ahuja, Jaishree Paul.   

Abstract

AIM: To study the interplay between butyrate concentration and butyrate-producing bacteria in fecal samples of ulcerative colitis (UC) patients vs control individuals.
METHODS: Fecal samples were collected from 14 control individuals (hemorrhoid patients only) and 26 UC patients (severe: n = 12, moderate: n = 6, remission: n = 8), recruited by the gastroenterologist at the Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India. Disease activity in UC patients was determined by clinical colitis activity index. We employed fluorescent in situ hybridization in combination with flow cytometry to enumerate the clostridium cluster population targeted by 16S rRNA gene probe. Major butyrate-producing species within this cluster were quantified to see if any change existed in control vs UC patients with different disease activity. This observed change was further validated by quantitative polymerase chain reaction. In addition to this, we carried out gas chromatography to evaluate the changes in concentration of major short chain fatty acids (SCFAs), namely acetate, n-butyrate, iso-butyrate, in the above samples. Student t test and Graph pad prism-6 were used to compare the data statistically.
RESULTS: There was a significant decrease of Clostridium coccoides (control, 25.69% ± 1.62% vs severe, 9.8% ± 2.4%, P = 0.0001) and Clostridium leptum clusters (control, 13.74% ± 1.05% vs severe, 6.2% ± 1.8%, P = 0.0001) in fecal samples of UC patients. Furthermore, we demonstrated that some butyrate-producing members of the clostridial cluster, like Fecalibacterium prausnitzii (control, 11.66% ± 1.55% vs severe, 6.01% ± 1.6%, P = 0.0001) and Roseburia intestinalis (control, 14.48% ± 1.52% vs severe, 9% ± 1.83%, P = 0.02) were differentially present in patients with different disease activity. In addition, we also demonstrated decreased concentrations of fecal SCFAs, especially of n-butyrate (control, 24.32 ± 1.86 mmol/μL vs severe, 12.74 ± 2.75 mmol/μL, P = 0.003), iso-butyrate (control, 1.70 ± 0.41 mmol/μL vs severe, 0.68 ± 0.24 mmol/μL, P = 0.0441) and acetate (control, 39.51 ± 1.76 mmol/μL vs severe, 32.12 ± 2.95 mmol/μL, P = 0.047), in the fecal samples of UC patients. The observed decrease of predominant butyrate producers of clostridial clusters correlated with the reduced SCFA levels in active UC patients. This was further confirmed by the restoration in the population of some butyrate producers with simultaneous increase in the level of SCFA in remission samples.
CONCLUSION: Our observations indicate that decreases in members of the clostridial cluster resulting in reduced butyrate levels contribute to the etiology of UC.

Entities:  

Keywords:  Clostridial cluster; Fecal microbiota; Fluorescent in situ hybridization-flow cytometry; Quantitative polymerase chain reaction; Short chain fatty acids; Ulcerative colitis

Mesh:

Substances:

Year:  2013        PMID: 23801832      PMCID: PMC3683678          DOI: 10.3748/wjg.v19.i22.3404

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

1.  Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach.

Authors:  C Manichanh; L Rigottier-Gois; E Bonnaud; K Gloux; E Pelletier; L Frangeul; R Nalin; C Jarrin; P Chardon; P Marteau; J Roca; J Dore
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

Review 2.  Physiology and ecology of the sulphate-reducing bacteria.

Authors:  G R Gibson
Journal:  J Appl Bacteriol       Date:  1990-12

3.  Fluorescent-oligonucleotide probing of whole cells for determinative, phylogenetic, and environmental studies in microbiology.

Authors:  R I Amann; L Krumholz; D A Stahl
Journal:  J Bacteriol       Date:  1990-02       Impact factor: 3.490

4.  Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in fecal samples.

Authors:  P S Langendijk; F Schut; G J Jansen; G C Raangs; G R Kamphuis; M H Wilkinson; G W Welling
Journal:  Appl Environ Microbiol       Date:  1995-08       Impact factor: 4.792

5.  Quantification of uncultured Ruminococcus obeum-like bacteria in human fecal samples by fluorescent in situ hybridization and flow cytometry using 16S rRNA-targeted probes.

Authors:  Erwin G Zoetendal; Kaouther Ben-Amor; Hermie J M Harmsen; Frits Schut; Antoon D L Akkermans; Willem M de Vos
Journal:  Appl Environ Microbiol       Date:  2002-09       Impact factor: 4.792

6.  Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers.

Authors:  Luying Peng; Zhong-Rong Li; Robert S Green; Ian R Holzman; Jing Lin
Journal:  J Nutr       Date:  2009-07-22       Impact factor: 4.798

7.  Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine.

Authors:  Sylvia H Duncan; Adela Barcenilla; Colin S Stewart; Susan E Pryde; Harry J Flint
Journal:  Appl Environ Microbiol       Date:  2002-10       Impact factor: 4.792

Review 8.  An update on the epidemiology of inflammatory bowel disease in Asia.

Authors:  Kelvin T Thia; Edward V Loftus; William J Sandborn; Suk-Kyun Yang
Journal:  Am J Gastroenterol       Date:  2008-12       Impact factor: 10.864

9.  A simple clinical colitis activity index.

Authors:  R S Walmsley; R C Ayres; R E Pounder; R N Allan
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

10.  Short-chain fatty acid topical treatment in distal ulcerative colitis.

Authors:  P Vernia; A Marcheggiano; R Caprilli; G Frieri; G Corrao; D Valpiani; M C Di Paolo; P Paoluzi; A Torsoli
Journal:  Aliment Pharmacol Ther       Date:  1995-06       Impact factor: 8.171

View more
  68 in total

Review 1.  Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases.

Authors:  Shivani Ghaisas; Joshua Maher; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2015-11-26       Impact factor: 12.310

2.  Is the emergence of inflammatory bowel disease a prime example of "the third epidemiological transition"?

Authors:  Saurabh Kedia; Vineet Ahuja
Journal:  Indian J Gastroenterol       Date:  2018-06-12

Review 3.  Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities.

Authors:  Kelley R Jordan; Brett R Loman; Michael T Bailey; Leah M Pyter
Journal:  Cancer       Date:  2018-07-05       Impact factor: 6.860

4.  The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis.

Authors:  Asuka Yasueda; Tsunekazu Mizushima; Riichiro Nezu; Ryoko Sumi; Mamoru Tanaka; Junichi Nishimura; Yasuyuki Kai; Masaki Hirota; Hideki Osawa; Kiyokazu Nakajima; Masaki Mori; Toshinori Ito
Journal:  Surg Today       Date:  2015-10-29       Impact factor: 2.549

5.  Antibiotic Treatment Induces Long-lasting Changes in the Fecal Microbiota that Protect Against Colitis.

Authors:  Naomi L Ward; Caleb D Phillips; Deanna D Nguyen; Nanda Kumar N Shanmugam; Yan Song; Richard Hodin; Hai Ning Shi; Bobby J Cherayil; Allan M Goldstein
Journal:  Inflamm Bowel Dis       Date:  2016-10       Impact factor: 5.325

Review 6.  Enteric microbiota leads to new therapeutic strategies for ulcerative colitis.

Authors:  Wei-Xu Chen; Li-Hua Ren; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 7.  Determinants of IBD Heritability: Genes, Bugs, and More.

Authors:  Williams Turpin; Ashleigh Goethel; Larbi Bedrani; Kenneth Croitoru Mdcm
Journal:  Inflamm Bowel Dis       Date:  2018-05-18       Impact factor: 5.325

Review 8.  Advances in treatment of ulcerative colitis with herbs: from bench to bedside.

Authors:  Ping Wan; Hao Chen; Yuan Guo; Ai-Ping Bai
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 9.  Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.

Authors:  Reena Kumari; Senthilnathan Palaniyandi; Gerhard Carl Hildebrandt
Journal:  Dig Dis Sci       Date:  2018-12-07       Impact factor: 3.199

Review 10.  Gut microbiome, gut function, and probiotics: Implications for health.

Authors:  Neerja Hajela; B S Ramakrishna; G Balakrish Nair; Philip Abraham; Sarath Gopalan; Nirmal K Ganguly
Journal:  Indian J Gastroenterol       Date:  2015-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.